secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2026-07-23T12:05:26+00:00
Accession:  0001493152-26-034334
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics raises $3M, extends runway to Q2 2027, advances NB1 study
------------------------------------------------------------------------

- Completed $3.0M private placement with healthcare-focused institutional investor; warrants could add up to $6.0M if exercised.
- Operating runway extended through Q2 2027; proceeds to fund clinical trials, patent portfolio, and working capital.
- NB1 first-in-human pilot study enrollment expected to complete by year-end 2026; interim updates possible.
- Validated shelf life of rhNELL-1 protein extended to 29 months, up from 24 months in December 2025.
- CEO Jeff Frelick highlights progress on 2026 priorities: clinical execution, product stability, IP protection, capital visibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315226034334/0001493152-26-034334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315226034334/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-034334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer